XORTX Therapeutics Files August 2024 Report
Ticker: XRTX · Form: 6-K · Filed: Aug 22, 2024 · CIK: 1729214
Sentiment: neutral
Topics: reporting, shareholder-meeting, corporate-governance
TL;DR
XORTX filed its August 6-K, including meeting docs. Nothing major, just housekeeping.
AI Summary
XORTX Therapeutics Inc. filed a Form 6-K on August 22, 2024, reporting for the month of August 2024. The filing includes notices and information circulars related to their Annual and Special Meeting. The company is incorporated in Alberta, Canada, and its fiscal year ends on December 31.
Why It Matters
This filing provides essential documentation for XORTX's shareholder meeting, impacting corporate governance and investor relations.
Risk Assessment
Risk Level: low — This filing is primarily administrative, containing meeting notices and circulars, with no new financial or operational disclosures that would immediately impact risk.
Key Players & Entities
- XORTX Therapeutics Inc. (company) — Registrant
- Allen Davidoff (person) — Chief Executive Officer
- August 2024 (date) — Reporting period
- August 22, 2024 (date) — Filing date
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report for the month of August 2024 and to provide documentation related to XORTX Therapeutics Inc.'s Annual and Special Meeting, including the notice, management information circular, and proxy.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed with the SEC on August 22, 2024.
What is the fiscal year end for XORTX Therapeutics Inc.?
XORTX Therapeutics Inc.'s fiscal year ends on December 31.
Who signed this report on behalf of XORTX Therapeutics Inc.?
Allen Davidoff, Chief Executive Officer, signed this report on behalf of XORTX Therapeutics Inc.
What exhibits are included with this filing?
This filing includes Exhibit 99.1 (Annual and Special Meeting Notice), Exhibit 99.2 (Annual and Special Meeting Management Information Circular), and Exhibit 99.3 (Annual and Special Meeting Proxy).
Filing Stats: 148 words · 1 min read · ~1 pages · Grade level 10.4 · Accepted 2024-08-22 07:00:09
Filing Documents
- f6k_082124.htm (6-K) — 7KB
- exh_991.htm (EX-99.1) — 7KB
- exh_992.htm (EX-99.2) — 492KB
- exh_993.htm (EX-99.3) — 1KB
- cumulativer.jpg (GRAPHIC) — 18KB
- lhlogo.jpg (GRAPHIC) — 3KB
- logo.jpg (GRAPHIC) — 11KB
- mail.jpg (GRAPHIC) — 1KB
- phone.jpg (GRAPHIC) — 1KB
- web.jpg (GRAPHIC) — 1KB
- exh993_1.jpg (GRAPHIC) — 941KB
- exh993_2.jpg (GRAPHIC) — 741KB
- 0001171843-24-004892.txt ( ) — 2870KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-40858 XORTX Therapeutics Inc. 3710 – 33 rd Street NW, Calgary, Alberta, T2L 2M1 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. XORTX THERAPEUTICS INC. (Registrant) Date: August 21, 2024 By: /s/ Allen Davidoff Name: Allen Davidoff Title: Chief Executive Officer EXHIBIT INDEX 99.1 Annual and Special Meeting Notice 99.2 Annual and Special Meeting Management Information Circular 99.3 Annual and Special Meeting Proxy